EyenoviaEYEN
EYEN
About: Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.
Employees: 57
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
2% less capital invested
Capital invested by funds: $7M [Q2] → $6.84M (-$157K) [Q3]
4.55% less ownership
Funds ownership: 21.87% [Q2] → 17.32% (-4.55%) [Q3]
18% less funds holding
Funds holding: 60 [Q2] → 49 (-11) [Q3]
36% less call options, than puts
Call options by funds: $7K | Put options by funds: $11K
60% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 20
61% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 18
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$2
2,245%
upside
Avg. target
$2
2,245%
upside
High target
$2
2,245%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
HC Wainwright & Co. Matthew Caufield 24% 1-year accuracy 12 / 50 met price target | 2,245%upside $2 | Neutral Downgraded | 18 Nov 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering
NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that it has entered into a securities purchase agreement with a healthcare focused institutional investor for the purchase and sale of 20,085,025 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 40,170,050 shares of common stock in a registered direct offering at a combined offering price of $0.0969 per share and accompanying warrants. The warrants will have an exercise price of $0.0969 per share, will be exercisable commencing six months from the date of issuance or, if required by The Nasdaq Capital Market, upon receipt of approval of the Company's stockholders, and will expire five years from the initial exercise date. The closing of the offering is expected to take place on or about December 9, 2024, subject to the satisfaction of customary closing conditions.
Neutral
GlobeNewsWire
4 weeks ago
Eyenovia Provides Update on Restructuring Efforts
Avenue Capital agrees to Company's deferral of principal and interest payments on its outstanding debt until the end of February 2025
Negative
Zacks Investment Research
1 month ago
Eyenovia Stock Tumbles on Termination of Phase III Myopia Study
EYEN stock craters on the decision to terminate late-stage myopia study of MicroPine following negative feedback from an independent Data Review Committee.
Negative
Benzinga
1 month ago
Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline
On Friday, Eyenovia, Inc. EYEN stock is trading lower after an update from the Phase 3 CHAPERONE study evaluating its proprietary drug-device combination of low-dose atropine in the company's Optejet dispensing platform pediatric progressive myopia.
Negative
Reuters
1 month ago
Eyenovia to discontinue late-stage study for eye drug
Eyenovia said on Friday it would terminate a late-stage study testing its experimental drug-device combination for pediatric progressive myopia as it failed to meet the main goal.
Neutral
GlobeNewsWire
1 month ago
Eyenovia Provides Update on Phase 3 CHAPERONE Study
A review of study data by an independent Data Review Committee found that CHAPERONE is not meeting its primary three-year efficacy endpoint
Neutral
Seeking Alpha
1 month ago
Eyenovia, Inc. (EYEN) Q3 2024 Earnings Call Transcript
Eyenovia, Inc. (NASDAQ:EYEN ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Eric Ribner - IR Michael Rowe - CEO Bren Kern - COO Andy Jones - CFO Conference Call Participants Matthew Caufield - H.C. Wainwright Matt Kaplan - Ladenburg Thalmann Lachlan Hanbury-Brown - William Blair Kemp Dolliver - Brookline Capital Markets Len Yaffe - Stoc Doc Partners Operator Greetings and welcome to Eyenovia's Third Quarter 2024 Earnings Call.
Negative
Zacks Investment Research
1 month ago
Eyenovia, Inc. (EYEN) Reports Q3 Loss, Misses Revenue Estimates
Eyenovia, Inc. (EYEN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.18 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th
Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT
Neutral
GlobeNewsWire
2 months ago
Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo
Presentation details efficacy and tolerability results from the successful Phase 3 program that led to FDA approval of clobetasol propionate suspension 0.05% for pain and inflammation following ocular surgery Presentation details efficacy and tolerability results from the successful Phase 3 program that led to FDA approval of clobetasol propionate suspension 0.05% for pain and inflammation following ocular surgery
Charts implemented using Lightweight Charts™